Floatz logo

2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER

MCI-AD, Early Stage Alzheimer's Disease

Medical University of LodzSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

316 Active assets in the MCI-AD, Early Stage Alzheimer's Disease cohort.

Asset / SponsorPhaseRating
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE
Akiva Mintz
Phase 4BBB
Namenda
Carnot Laboratories
Phase 4BBB
Cipralex
NYU Langone Health
Phase 4BBB
Rivastigmine
Anhui Provincial Hospital
Phase 4BBB
Sertraline
AstraZeneca
Phase 4BBB

View all 50 →

Same molecule, other indications

2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER is also rated in:

relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
multiple sclerosisDormant
BB
Indicative ·
67 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →